Should you buy Bio-Techne (TECH)?
Updated
Bio-Techne earns exceptional free cash flow at 274% of net income, holds a Piotroski financial health score of 8 out of 9, and maintains high gross margins — but the Protein Sciences segment represents 72% of revenue, top-line revenue has declined 2% year-over-year, and the stock is trading above its resistance take-profit target with negative asymmetry.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The Protein Sciences segment generates 72% of Bio-Techne's revenue, creating a single-segment concentration that amplifies exposure to the academic, biopharmaceutical, and industrial life sciences spending cycles — a risk factor noted in the 10-K annual filing. Bear case | Protein Sciences revenue share falls below 65% within 12 months as other segments grow faster, or the segment itself grows faster than 10% per year. | →Stable |
| CounterDominant market position in high-purity proteins and recombinant cytokines is a scientific moat that provides pricing power; the segment concentration reflects competitive strength in a niche where Bio-Techne is the reference standard for many research applications. | ||
Bio-Techne converts 274% of net income into free cash flow, indicating that reported earnings substantially understate the company's cash generation capability — a quality signal reflecting strong working capital management and asset-light characteristics in the life sciences reagents business. Quality breakdown | Free cash flow conversion stays above 200% of net income over the next four reported quarters. | →Stable |
| CounterFree cash flow far exceeding net income can reflect deferred investment that will eventually require capital expenditure catch-up; a 72% concentration in the Protein Sciences segment means that a demand slowdown in that segment immediately impairs the cash generation story. | ||
Revenue declined 2% year-over-year, suggesting the core business is contracting modestly even as cash flow remains strong — a divergence that needs to reverse for the business to sustain its quality metrics over the medium term. Growth breakdown | Revenue growth turns positive on a year-over-year basis in at least 3 of the next 4 reported quarters. | →Stable |
| CounterBiotech research tools companies often show lumpy revenue due to large contract timing; the free cash flow strength suggests the decline is not yet impacting underlying profitability and may represent a temporary pause in a durable growth business. | ||
The Protein Sciences segment generates 72% of Bio-Techne's revenue, creating a single-segment concentration that amplifies exposure to the academic, biopharmaceutical, and industrial life sciences spending cycles — a risk factor noted in the 10-K annual filing.
→Stable- Expectation
- Protein Sciences revenue share falls below 65% within 12 months as other segments grow faster, or the segment itself grows faster than 10% per year.
CounterDominant market position in high-purity proteins and recombinant cytokines is a scientific moat that provides pricing power; the segment concentration reflects competitive strength in a niche where Bio-Techne is the reference standard for many research applications.
Bio-Techne converts 274% of net income into free cash flow, indicating that reported earnings substantially understate the company's cash generation capability — a quality signal reflecting strong working capital management and asset-light characteristics in the life sciences reagents business.
→Stable- Expectation
- Free cash flow conversion stays above 200% of net income over the next four reported quarters.
CounterFree cash flow far exceeding net income can reflect deferred investment that will eventually require capital expenditure catch-up; a 72% concentration in the Protein Sciences segment means that a demand slowdown in that segment immediately impairs the cash generation story.
Revenue declined 2% year-over-year, suggesting the core business is contracting modestly even as cash flow remains strong — a divergence that needs to reverse for the business to sustain its quality metrics over the medium term.
→Stable- Expectation
- Revenue growth turns positive on a year-over-year basis in at least 3 of the next 4 reported quarters.
CounterBiotech research tools companies often show lumpy revenue due to large contract timing; the free cash flow strength suggests the decline is not yet impacting underlying profitability and may represent a temporary pause in a durable growth business.
▸ Show 1 more pillar▾ Show fewer
The stock at $56.17 is trading above the take-profit resistance level of $55.37, meaning the current price already exceeds the near-term technical target — with negative 1.4% upside and an asymmetry ratio of negative 0.3, creating an unfavorable risk-to-reward profile for new buyers.
→Stable- Expectation
- Price pulls back to at least $52, more than 7% below the current $56.17, to restore a favorable entry with risk-to-reward ratio above 1.5.
CounterResistance levels are not hard ceilings; a stock with strong fundamentals and consistent free cash flow can trade above technical resistance for extended periods if analyst targets are revised upward after positive earnings delivery.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Bio-Techne converts 274% of net income into free cash flow, indicating that reported earnings substantially understate the company's cash generation capability — a quality signal reflecting strong working capital management and asset-light characteristics in the life sciences reagents business.
Trip ifFree cash flow conversion falls below 150% of net income, more than 124 percentage points below the current 274% level.
- P2The Protein Sciences segment generates 72% of Bio-Techne's revenue, creating a single-segment concentration that amplifies exposure to the academic, biopharmaceutical, and industrial life sciences spending cycles — a risk factor noted in the 10-K annual filing.
Trip ifProtein Sciences segment revenue declines by more than 10% year-over-year in any reported quarter.
- P3Revenue declined 2% year-over-year, suggesting the core business is contracting modestly even as cash flow remains strong — a divergence that needs to reverse for the business to sustain its quality metrics over the medium term.
Trip ifRevenue growth remains below -5% year-over-year for more than 3 consecutive reported quarters.
- P4The stock at $56.17 is trading above the take-profit resistance level of $55.37, meaning the current price already exceeds the near-term technical target — with negative 1.4% upside and an asymmetry ratio of negative 0.3, creating an unfavorable risk-to-reward profile for new buyers.
Trip ifStock price rises above $62, more than 10% above the current $56.17, without a corresponding analyst target increase above $67.
How the engine reached this verdict
TrendMatrix's engine output for Bio-Techne Corp (TECH) is SELL_IF_HOLDING with medium conviction, score 5.6/10 at $70.43. The F-path SELL output reflects an overall score of 5.6 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -1.61 is supplementary context, not the trigger.
The engine's exit framework anchors to a tactical sell band near $70.43, with structural invalidation at $65.45. The asymmetric R:R against a reversal hypothesis is -0.24 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Positive momentum. On the bear side: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining; Near 52-week high (2.5% away). Active engine warnings: V8: Target reached (-24.2% upside), V9 Gate Failed: ASYMMETRY:-1.6=NEGATIVE.
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:8.6>=5.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates TECH — 10-dimension breakdown →
Bull case
- ▸Positive momentum
Bear case
- ▸Concentration risk — Product: Protein Sciences segment (72.0%)
- ▸Analyst target reached - limited upside remaining
- ▸Near 52-week high (2.5% away)